Deals Rumor Mill: Amgen, Newfield, Verizon

Law360, New York (August 15, 2013, 3:55 PM EDT) -- Amgen Inc.’s $9.5 billion takeover of rival Onyx Pharmaceuticals Inc. is being held up as the two lock horns over access to data from an ongoing clinical trial of one of Onyx’s showcase cancer treatments, Bloomberg reported on Thursday. The news comes after earlier reports indicated that the two were closing in on a $130-per-share deal, sweetened from a previously rejected Amgen approach. Onyx is apparently prepared to accept the consideration but does not want to preliminarily view data from the trial, which is currently underway,...
To view the full article, register now.